Clinical Report: Sexual Dysfunction Linked to Antidepressant and Antipsychotic Use

Overview

Sexual dysfunction is prevalent among patients treated with antidepressants and antipsychotics. This review highlights the mechanisms, assessment, and management strategies for addressing this issue in clinical practice.

Background

Sexual dysfunction is a significant concern in patients with depressive and psychotic disorders. It can arise from the underlying illness, pharmacotherapy, or a combination of factors.

Data Highlights

No numerical data available in the source material.

Key Findings

• Sexual dysfunction is common in patients treated with antidepressants and antipsychotics.
• Strongly serotonergic antidepressants, particularly SSRIs and venlafaxine, are associated with a higher risk of treatment-emergent sexual dysfunction.
• Prolactin-elevating antipsychotics, such as risperidone and paliperidone, generally have a less favorable sexual tolerability profile.
• Non-serotonergic antidepressants like bupropion and mirtazapine show a more favorable sexual side effect profile.
• Direct questioning and validated instruments are essential for the reliable detection of sexual dysfunction in patients.
• Systematic assessment of sexual dysfunction should be integrated into routine treatment planning and follow-up.

Clinical Implications

Clinicians should assess sexual function in patients receiving antidepressants and antipsychotics, as these medications can impact sexual health.

Conclusion

Sexual dysfunction is an important aspect of psychopharmacology that requires assessment and management.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Author(s)/Org, Source, Year -- Title
6. Author(s)/Org, Source, Year -- Title
7. Author(s)/Org, Source, Year -- Title
8. Author(s)/Org, Source, Year -- Title
9. Author(s)/Org, Source, Year -- Title
10. Author(s)/Org, Source, Year -- Title
11. Sexual dysfunction associated with selective serotonin reuptake inhibitors in adults with depression: a systematic review and meta-analysis - PMC
12. Sexual health in schizophrenia: beyond the prolactin lens | The Journal of Sexual Medicine | Oxford Academic
13. Definitions, classification, and epidemiology of sexual dysfunction: a consensus statement from the Fifth International Consultation on Sexual Medicine 2024
14. Recommendations | Psychosis and schizophrenia in adults: prevention and management | Guidance | NICE
15. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia - PubMed
16. Recommendations for the Deprescribing of Psychotropic Medications: A Consensus Statement From the American Society of Clinical Psychopharmacology Task Force | Clinical Pharmacy and Pharmacology | JAMA Network Open | JAMA Network
17. 11 June 20191
18. Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose–Response Meta-analysis | CNS Drugs | Springer Nature Link
19. Managing schizophrenia with affective, sexual, metabolic and substance-use comorbidities: pharmacological considerations from an expert consensus - PMC
20. VA/DoD_Clinical_Practice_Guideline_for_the_Management_of_Major_Depressive_Disorder_(MDD)